Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Quiapeg Pharmaceuticals AB currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners, which indicates that each matter is being evaluated by a separate individual. Despite having multiple examiners, the prosecution is concentrated within 1 distinct art unit, suggesting a very specific technical focus for the company's current applications.
The busiest examiner for this portfolio is Lieb, Jeanette M, who is managing 1 pending office action. Since there are multiple pending office actions in total, the workload is divided between the distinct examiners. For a practitioner, this means that while the examiners are different, they are both operating within the same 1 distinct art unit, which may lead to more consistent procedural expectations.
The concentration in the single art unit is a notable feature of this portfolio, as it simplifies the organizational landscape for the applicant. However, the involvement of distinct examiners still requires the company to tailor its arguments to different perspectives. With the pending office actions active, the company maintains a focused but multi-pronged approach to its patent prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIEB, JEANETTE M | 1 | 79.9% | +17.2% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18234142 | RELEASABLE CONJUGATES | JARRELL, NOBLE E | 46d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18444317 | RELEASABLE GLP-1 CONJUGATES | LIEB, JEANETTE M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18444317 | RELEASABLE GLP-1 CONJUGATES | LIEB, JEANETTE M | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18444317 | RELEASABLE GLP-1 CONJUGATES | LIEB, JEANETTE M | — | §101DP | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18234142 | RELEASABLE CONJUGATES | JARRELL, NOBLE E | 1699 | §112 | Non-Final OA | 46d | Pending | Aug 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial